AstraZeneca and Forest Laboratories, Inc. announced today that ceftazidime/avibactam (CAZ-AVI) will enter phase III trials to investigate efficacy in treating hospitalised patients with serious Gram-negative bacterial infections including Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI). CAZ-AVI combines a broad-spectrum cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam, formerly NXL104) to overcome antibiotic-resistance and treat the increasing number of infections resistant to existing therapies.
First results from a large-scale Phase III trial of RTS,S, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington.
US based Neurocrine Biosciences has started a second double-blind, placebo controlled, randomized cross-over Phase II trial to evaluate NBI- 98854.
The Cohort Review Committee has approved Scancell to further escalate cancer vaccine SCIB1 dose to 4mg from the current 2mg in the Phase I clinical trial and recruitment of the final group of patients as planned.
Acetylon Pharmaceuticals has started treating patients in a three-part Phase 1-2a trial to evaluate ACY-1215 in adult patients suffering from relapsed and relapsed/refractory multiple myeloma.
Bionor Pharma is set to initiate a double blinded, randomized and placebo-controlled trial to evaluate HIV-vaccine candidate Vacc-4x in combination with Revlimid.Revlimid is indicated as a treatment for multiple myeloma and anemia due to myelodysplastic syndrome linked with a deletion in the long arm of the fifth chromosome.
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) have commenced a Phase IIb trial to investigate a new experimental tuberculosis vaccine in TB patients with human immunodeficiency virus (HIV) infection.